• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To Forte Biosciences (FBRX) Widening Losses But Slightly Improved Per-Share Results

    Simply Wall St·08/15/2026 22:26:35
    Listen to the news
    • Forte Biosciences, Inc. reported past second-quarter and first-half 2026 results, with net losses of US$23.33 million and US$45.47 million respectively, both higher than the prior-year periods.
    • Despite the larger overall losses, basic loss per share from continuing operations narrowed slightly to US$2.18 from US$2.32 a year earlier, highlighting the impact of share count and capital structure on per-share results.
    • Next, we’ll examine how the widening net loss alongside a slightly improved loss per share shapes Forte Biosciences’ investment narrative.

    Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    What Is Forte Biosciences' Investment Narrative?

    For someone owning Forte Biosciences today, the core belief is less about a standalone turnaround and more about the pending sale to argenx and the value of FB102 inside a larger platform. The latest results reinforce that Forte remains a pre-revenue biotech burning significant cash, with losses widening in the first half of 2026 even as loss per share ticked slightly lower. On their own, these numbers probably do not change the near-term story much, because the key short-term catalyst is now the US$77 per share cash tender offer and its successful closing, alongside any incremental clinical color on FB102. Instead, the earnings print mostly sharpens the main risk: Forte’s dependence on continued external funding and deal completion while running at higher loss levels.

    However, there is one deal-related risk here that shareholders should not ignore. The analysis detailed in our Forte Biosciences valuation report hints at an inflated share price compared to its estimated value.

    Exploring Other Perspectives

    FBRX 1-Year Stock Price Chart
    FBRX 1-Year Stock Price Chart

    The single US$73.8 fair value estimate from the Simply Wall St Community sits just below the agreed US$77 cash offer, reminding you that individual views can cluster tightly. Set that against rising losses and reliance on the argenx transaction, and it becomes clear why many market participants are now focused less on long-term upside and more on deal certainty and execution risk. To really understand where you stand, you need to weigh these contrasting perspectives side by side.

    Explore another fair value estimate on Forte Biosciences - why the stock might be worth just $73.80!

    The Verdict Is Yours

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Forte Biosciences research is our analysis highlighting 5 important warning signs that could impact your investment decision.
    • Our free Forte Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Forte Biosciences' overall financial health at a glance.

    Ready To Venture Into Other Investment Styles?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.